Aethlon Medical Faces Delisting Notice

TL;DR

AETHLON MEDICAL INC (AEMD) got a notice about failing to meet listing rules - could get delisted.

AI Summary

Aethlon Medical, Inc. filed an 8-K on January 8, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in San Diego, California, and was incorporated in Nevada.

Why It Matters

This filing indicates potential issues with Aethlon Medical's compliance with stock exchange listing standards, which could lead to the company's shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.

Key Players & Entities

• Aethlon Medical, Inc. (company) — Registrant
• January 7, 2025 (date) — Earliest event reported
• January 8, 2025 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
• $1.00 — any's common stock had closed below the $1.00 per share minimum required for continue

Filing Documents

• aethlon_8k.htm (8-K) — 27KB
• 0001683168-25-000150.txt ( ) — 198KB
• aemd-20250107.xsd (EX-101.SCH) — 3KB
• aemd-20250107_lab.xml (EX-101.LAB) — 33KB
• aemd-20250107_pre.xml (EX-101.PRE) — 24KB
• aethlon_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 27, 2024, Aethlon Medical Inc., a Nevada Corporation (the "Company") received a letter (the "Notice") from The Nasdaq Stock Market ("Nasdaq") advising the Company that for 31 consecutive trading days preceding the date of the Notice, the bid price of the Company's common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)(the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until December 24, 2024, to regain compliance with the Minimum Bid Requirement. On January 7, 2025, the Company received a letter from Nasdaq (the "Extension Notice") advising that the Company has been granted a 180-day extension, or until June 23, 2025, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to June 23, 2025, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement. The Extension Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market and does not affect the Company's reporting requirements with the Securities and Exchange Commission. If the Company does not regain compliance with the Minimum Bid Price Requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal the delisting determ

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2025 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR